CRNX רווח נקי למניה ב-12 החודשים האחרונים crinetics.com

The niche nature of orphan pathologies limits the pool of competitors, creating a foundation for a future monopoly for Crinetics Pharmaceuticals (CRNX). Net income per share over the last 12 months visualizes these expectations, where -5.09 indicates the current level of the metric. Growth prospects are bolstered by the development of paltusotine and the potential for acquisition by industry behemoths. The current lack of profitability is offset by a significant cash reserve from previous investment rounds.
פילוחים אנליטיים ודוחות נתונים של חברת Crinetics Corp (CRNX)

For Crinetics Pharmaceuticals (CRNX), which is currently in the product cycle phase within endocrinology, the rolling annual earnings per share reflects the efficiency of innovation capitalization regardless of macroeconomic conditions. This metric is calculated by dividing the total net income over the last twelve months by the total number of outstanding shares, determining the real equity return of the business and the fundamental stability of investments in the biopharmaceutical sector.